Switch to:

Arrowhead Pharmaceuticals Debt-to-Equity

: 0.04 (As of Jun. 2020)
View and export this data going back to 1997. Start your Free Trial

Arrowhead Pharmaceuticals's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $1.0 Mil. Arrowhead Pharmaceuticals's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2020 was $20.4 Mil. Arrowhead Pharmaceuticals's Total Stockholders Equity for the quarter that ended in Jun. 2020 was $493.1 Mil. Arrowhead Pharmaceuticals's debt to equity for the quarter that ended in Jun. 2020 was 0.04.

A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.

NAS:ARWR' s Debt-to-Equity Range Over the Past 10 Years
Min: -0.57   Med: 0.03   Max: 9.01
Current: 0.04

-0.57
9.01

During the past 13 years, the highest Debt-to-Equity Ratio of Arrowhead Pharmaceuticals was 9.01. The lowest was -0.57. And the median was 0.03.

NAS:ARWR's Debt-to-Equity is ranked higher than
67% of the 1026 Companies
in the Biotechnology industry.

( Industry Median: 0.09 vs. NAS:ARWR: 0.04 )

Arrowhead Pharmaceuticals Debt-to-Equity Historical Data

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.

* Premium members only.

Arrowhead Pharmaceuticals Annual Data
Sep10 Sep11 Sep12 Sep13 Sep14 Sep15 Sep16 Sep17 Sep18 Sep19
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.01 0.03 0.03 0.02 0.00

Arrowhead Pharmaceuticals Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Debt-to-Equity Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.03 0.03 0.04

Competitive Comparison
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap.


Arrowhead Pharmaceuticals Debt-to-Equity Distribution

* The bar in red indicates where Arrowhead Pharmaceuticals's Debt-to-Equity falls into.



Arrowhead Pharmaceuticals Debt-to-Equity Calculation

Debt to Equity measures the financial leverage a company has.

Arrowhead Pharmaceuticals's Debt to Equity Ratio for the fiscal year that ended in Sep. 2019 is calculated as

Arrowhead Pharmaceuticals's Debt to Equity Ratio for the quarter that ended in Jun. 2020 is calculated as

* All numbers are in millions except for per share data and ratio. All numbers are in their local exchange's currency.


Arrowhead Pharmaceuticals  (NAS:ARWR) Debt-to-Equity Explanation

In the calculation of Debt to Equity, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Stockholders Equity. In some calculations, Total Liabilities is used to for calculation.


Be Aware

Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.


Arrowhead Pharmaceuticals Debt-to-Equity Related Terms


Arrowhead Pharmaceuticals Debt-to-Equity Headlines

No Headline

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)